2022
Concomitant medication use in children with autism spectrum disorder: Data from the Autism Biomarkers Consortium for Clinical Trials
Shurtz L, Schwartz C, DiStefano C, McPartland JC, Levin AR, Dawson G, Kleinhans NM, Faja S, Webb SJ, Shic F, Naples AJ, Seow H, Bernier RA, Chawarska K, Sugar CA, Dziura J, Senturk D, Santhosh M, Jeste SS. Concomitant medication use in children with autism spectrum disorder: Data from the Autism Biomarkers Consortium for Clinical Trials. Autism 2022, 27: 952-966. PMID: 36086805, PMCID: PMC9995606, DOI: 10.1177/13623613221121425.Peer-Reviewed Original ResearchMeSH KeywordsAntipsychotic AgentsAutism Spectrum DisorderAutistic DisorderChildHumansPsychotropic DrugsConceptsConcomitant psychotropic medicationsPsychotropic medicationsClinical trialsMedication useSchool-aged childrenClinical representativenessSelective serotonin reuptake inhibitorsConcomitant medication useVariety of medicationsAutism spectrum disorderSerotonin reuptake inhibitorsPsychotropic medication useNew treatment optionsGreater overall impairmentCentral nervous systemSpectrum disorderMedication classesReuptake inhibitorsAlpha agonistsTreatment optionsClinical endpointsInclusion criteriaStudy populationMedicationsNervous system
2018
Neurocognitive correlates of treatment response in children with Tourette's Disorder
Chang SW, McGuire JF, Walkup JT, Woods DW, Scahill L, Wilhelm S, Peterson AL, Dziura J, Piacentini J. Neurocognitive correlates of treatment response in children with Tourette's Disorder. Psychiatry Research 2018, 261: 464-472. PMID: 29407718, PMCID: PMC5809184, DOI: 10.1016/j.psychres.2017.12.066.Peer-Reviewed Original ResearchConceptsAttention deficit hyperactivity disorderBehavior therapyNeurocognitive functioningCo-occurring attention-deficit hyperactivity disorderPerformance speedTourette's disorderBrief neurocognitive batteryDeficit hyperactivity disorderBehavior therapy groupSmall negative associationNeurocognitive predictorsNeurocognitive correlatesCognitive functioningNeurocognitive batteryHabit learningPositive treatment responseHyperactivity disorderMotor inhibitionGroup differencesNeurocognitive statusFunctioningGreater baselineMemoryYouthNegative association
2016
Weight Gain and Metabolic Consequences of Risperidone in Young Children With Autism Spectrum Disorder
Scahill L, Jeon S, Boorin SJ, McDougle CJ, Aman MG, Dziura J, McCracken JT, Caprio S, Arnold LE, Nicol G, Deng Y, Challa SA, Vitiello B. Weight Gain and Metabolic Consequences of Risperidone in Young Children With Autism Spectrum Disorder. Journal Of The American Academy Of Child & Adolescent Psychiatry 2016, 55: 415-423. PMID: 27126856, PMCID: PMC4851735, DOI: 10.1016/j.jaac.2016.02.016.Peer-Reviewed Original ResearchConceptsWaist circumferenceWeight gainWeek 24Metabolic syndromeWeek 16Homeostatic model assessment-insulin resistanceMetabolic consequencesModel assessment-insulin resistanceBody mass index z-scoreAssessment-insulin resistanceLiver function testsTrial of risperidoneIndex z-scoreAutism spectrum disorderRapid weight gainRisperidone exposureBlood lipidsRisperidone monotherapyRisperidone treatmentFunction testsNormal weightInsulin resistanceAlanine aminotransferaseSpectrum disorderBlood samples
2015
Sensitivity of the modified Children’s Yale–Brown Obsessive Compulsive Scale to detect change: Results from two multi-site trials
Scahill L, Sukhodolsky DG, Anderberg E, Dimitropoulos A, Dziura J, Aman MG, McCracken J, Tierney E, Hallett V, Katz K, Vitiello B, McDougle C. Sensitivity of the modified Children’s Yale–Brown Obsessive Compulsive Scale to detect change: Results from two multi-site trials. Autism 2015, 20: 145-152. PMID: 25882391, DOI: 10.1177/1362361315574889.Peer-Reviewed Original Research
2012
Brief Report: Social Disability in Autism Spectrum Disorder: Results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network Trials
Scahill L, Hallett V, Aman MG, McDougle CJ, Eugene Arnold L, McCracken JT, Tierney E, Deng Y, Dziura J, Vitiello B, the Research Units on Pediatric Psychopharmacology (RUPP) Autism Network). Brief Report: Social Disability in Autism Spectrum Disorder: Results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network Trials. Journal Of Autism And Developmental Disorders 2012, 43: 739-746. PMID: 23104617, PMCID: PMC3886122, DOI: 10.1007/s10803-012-1689-3.Peer-Reviewed Original ResearchConceptsSocial Withdrawal subscaleSocial disabilityWithdrawal subscaleAcute treatment trialsWeeks of treatmentDouble-blind conditionsAutism spectrum disorderMedication trialsActive treatmentTreatment trialsSpectrum disorderNetwork trialSecondary analysisRisperidoneTrialsPlaceboDisabilityParent trainingSubjectsDisordersTreatmentSubscalesUseful measureResearch UnitWeeks
2011
Effects of Risperidone and Parent Training on Adaptive Functioning in Children With Pervasive Developmental Disorders and Serious Behavioral Problems
Scahill L, McDougle CJ, Aman MG, Johnson C, Handen B, Bearss K, Dziura J, Butter E, Swiezy NG, Arnold LE, Stigler KA, Sukhodolsky DD, Lecavalier L, Pozdol SL, Nikolov R, Hollway JA, Korzekwa P, Gavaletz A, Kohn AE, Koenig K, Grinnon S, Mulick JA, Yu S, Vitiello B, Network R. Effects of Risperidone and Parent Training on Adaptive Functioning in Children With Pervasive Developmental Disorders and Serious Behavioral Problems. Journal Of The American Academy Of Child & Adolescent Psychiatry 2011, 51: 136-146. PMID: 22265360, PMCID: PMC3941712, DOI: 10.1016/j.jaac.2011.11.010.Peer-Reviewed Original ResearchAdaptation, PsychologicalAdolescentAntipsychotic AgentsAsperger SyndromeAutistic DisorderChecklistChildChild Behavior DisordersChild Development Disorders, PervasiveChild, PreschoolCombined Modality TherapyCommunicationCooperative BehaviorDose-Response Relationship, DrugEducationFemaleHumansMaleRisperidoneSocialization
2009
Medication and Parent Training in Children With Pervasive Developmental Disorders and Serious Behavior Problems: Results From a Randomized Clinical Trial
Aman MG, Mcdougle CJ, Scahill L, Handen B, Arnold LE, Johnson C, Stigler KA, Bearss K, Butter E, Swiezy NB, Sukhodolsky DD, Ramadan Y, Pozdol SL, Nikolov R, Lecavalier L, Kohn AE, Koenig K, Hollway JA, Korzekwa P, Gavaletz A, Mulick JA, Hall KL, Dziura J, Ritz L, Trollinger S, Yu S, Vitiello B, Wagner A, Network F. Medication and Parent Training in Children With Pervasive Developmental Disorders and Serious Behavior Problems: Results From a Randomized Clinical Trial. Journal Of The American Academy Of Child & Adolescent Psychiatry 2009, 48: 1143-1154. PMID: 19858761, PMCID: PMC3142923, DOI: 10.1097/chi.0b013e3181bfd669.Peer-Reviewed Original ResearchConceptsPervasive developmental disorderClinical trialsClinical Global Impressions-Improvement scoreAberrant Behavior Checklist IrritabilityParallel-group clinical trialParent trainingBehavioral problemsDevelopmental disordersRisperidone doseRisperidone monotherapyHyperactivity/noncompliance subscaleSevere behavioral problemsCOMB groupPT sessionsQuestionnaire scoresHSQ scoresMedicationsGreater reductionChildrenPrimary measureRisperidoneSignificant reductionStereotypic behaviorScoresDose